Real-world cost-effectiveness in chronic myeloid leukemia: the price of success during four decades of development from non-targeted treatment to imatinib

Adherence to BCR-ABL Inhibitors: Issues for CML Therapy

(2012) Elias Jabbour et al.   Clinical Lymphoma Myeloma & Leukemia

NICE guidance on dasatinib, high-dose imatinib, and nilotinib for patients with CML who are resistant or intolerant to imatinib

(2012) Scott Goulden et al.   LANCET ONCOLOGY

Challenges for Allogeneic Hematopoietic Stem Cell Transplantation in Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors

(2011) Anthony Oyekunle et al.   ACTA HAEMATOLOGICA

Good adherence to imatinib therapy among patients with chronic myeloid leukemia—a single-center observational study

(2011) Sofia Jönsson et al.   ANNALS OF HEMATOLOGY

Success Story of Targeted Therapy in Chronic Myeloid Leukemia: A Population-Based Study of Patients Diagnosed in Sweden From 1973 to 2008

(2011) Magnus Björkholm et al.   JOURNAL OF CLINICAL ONCOLOGY

Delivering affordable cancer care in high-income countries

(2011) Richard Sullivan et al.   LANCET ONCOLOGY

Cost utility of allogeneic stem cell transplantation with matched unrelated donor versus treatment with imatinib for adult patients with newly diagnosed chronic myeloid leukaemia

(2010) Lusine Breitscheidel   JOURNAL OF MEDICAL ECONOMICS

Quality of life and social integration after allogeneic hematopoietic SCT

(2008) S Bieri et al.   BONE MARROW TRANSPLANTATION

Updated Estimates of Survival and Cost Effectiveness for Imatinib versus Interferon-?? Plus Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukaemia

(2008) Shelby D Reed et al.   PHARMACOECONOMICS